Abstract 2534
Background
Radiomic signatures offer the potential to enhance clinical decision-making as on-treatment markers of efficacy to assess which patients (pts) should continue treatment. Using treatment-related radiomic signatures via quantitative, artificial intelligence (AI)-based analysis of computed tomography (CT) images, we evaluated early tumor changes in pts with sqNSCLC treated in 2 treatment groups: nivolumab (group A) or docetaxel (group B).
Methods
Data from pts with sqNSCLC were collected prospectively and analyzed retrospectively across 2 multicenter clinical trials (A, n = 92 CheckMate 017 [NCT01642004], CheckMate 063 [NCT01721759]; B, n = 50 CheckMate 017). For the current study, pts with a measurable lung lesion and baseline and on-treatment assessments (8 weeks) were randomized to training (T) or validation (V) datasets (A: 72T, 20V; B: 32T, 18V;). For each pt, the largest measurable lung tumor was segmented to extract 1,749 radiomic features. Pts were classified as treatment-sensitive or -resistant using median progression-free survival (PFS) calculated from pts included in this study (A, B). Using AI-based methodologies, up to 4 features were selected and combined to develop a signature score (range, 0-1) in the T datasets and applied to each pt in the V datasets to classify sensitivity to treatment.
Results
The radiomics features associated with treatment sensitivity in the T datasets were a decrease in tumor volume (A, B), infiltration of tumor boundaries (A), or tumor spatial heterogeneity (A). The radiomic signatures predicted treatment sensitivity in the V dataset of each study group (AUC [95% CI]: A, 0.77 [0.55-1.00]; B, 0.67 [0.37-0.96]).
Conclusions
AI-based CT imaging detected early changes in radiomic features from baseline to first on-treatment tumor assessment—decrease in tumor volume, tumor heterogeneity, and tumor infiltrativeness along boundaries—that were associated with sensitivity to treatment in pts with sqNSCLC, offering an approach that could guide clinical decision-making to continue or modify systemic therapies.
Clinical trial identification
CheckMate 017 [NCT01642004] July 17, 2012 (first posted date) CheckMate 063 [NCT01721759] November 6, 2012 (first posted date).
Editorial acknowledgement
Legal entity responsible for the study
Bristol-Myers Squibb and Columbia University Medical Center.
Funding
Bristol-Myers Squibb.
Disclosure
M. Fronheiser: Shareholder / Stockholder / Stock options, Full / Part-time employment: Bristol-Myers Squibb. S. Du: Shareholder / Stockholder / Stock options, Full / Part-time employment: Bristol-Myers Squibb. W. Hayes: Shareholder / Stockholder / Stock options, Full / Part-time employment: Bristol-Myers Squibb. D.K. Leung: Shareholder / Stockholder / Stock options, Full / Part-time employment: Bristol-Myers Squibb. A. Roy: Shareholder / Stockholder / Stock options, Full / Part-time employment: Bristol-Myers Squibb. L.H. Schwartz: Research grant / Funding (self), Member DSMB: Merck; Research grant / Funding (self), Member DSMB: Novartis; Research grant / Funding (self), Consultant endpoint analysis: Boehringer Ingelheim. All other authors have declared no conflicts of interest.
Resources from the same session
5822 - Greek nursing students experience facing death in clinical practice
Presenter: Maria Dimoula
Session: Poster Display session 3
Resources:
Abstract
2866 - HOPEVOL: Hospice care appropriate to the wishes and needs of patients in the palliative terminal phase.
Presenter: Merel van Klinken
Session: Poster Display session 3
Resources:
Abstract
829 - Mindfulness-based stress reduction in early palliative care for advanced cancer patients : an italian single-centre study. MINDEEP
Presenter: Emilia Gianotti
Session: Poster Display session 3
Resources:
Abstract
2702 - Optimising Inpatient Oncology Care
Presenter: Lisa Judge
Session: Poster Display session 3
Resources:
Abstract
1527 - Analysis on the Implementation Results of Family Sickbed for Oncology Patients in Dongshi Township Health Centers from 2015 to 2017
Presenter: Yayu Huang
Session: Poster Display session 3
Resources:
Abstract
2054 - Exploring needs for palliative care and quality of life for oncology patients with advanced disease who undergo radiotherapy
Presenter: Foteini Antonopoulou
Session: Poster Display session 3
Resources:
Abstract
5605 - Cytotoxic contamination in cancer care settings – Risks and safety awareness among cancer nurses
Presenter: Sandra Lundman Vikberg
Session: Poster Display session 3
Resources:
Abstract
5769 - Understanding Chemotherapy - group education sessions prior to commencing chemotherapy
Presenter: Aileen McHale
Session: Poster Display session 3
Resources:
Abstract
2620 - Estimation of HPQ-based absenteeism and presenteeism in cancer patients via ResearchKit
Presenter: Shunsuke Kondo
Session: Poster Display session 3
Resources:
Abstract
4705 - Identifying falls-related variables and risk factors in hospitalised cancer patients
Presenter: Maria Montserrat Martí Dillet
Session: Poster Display session 3
Resources:
Abstract